December 1990

Detection of Primary Colorectal Cancer With Indium 111 Monoclonal Antibody B72.3

Author Affiliations

From the Departments of Surgery (Drs Doerr and Baker) and Nuclear Medicine (Dr Abdel-Nabi), Veterans Affairs Medical Center, Buffalo, NY; Buffalo General Hospital and State University of New York at Buffalo (Drs Doerr, Baker, and Abdel-Nabi); and Department of Surgery, Tulane University School of Medicine, New Orleans, La (Dr Steinberg).

Arch Surg. 1990;125(12):1601-1605. doi:10.1001/archsurg.1990.01410240083016

• B72.3 is a murine monoclonal antibody of the immunoglobulin subclass IgG1 directed against TAG-72, a cell surface antigen present on colorectal carcinoma cells. We investigated the utility of scanning with indium 111–labeled B72.3 in 16 patients with a high clinical suspicion of or biopsy-proven primary colorectal cancer. Each patient received 1 or 2 mg of B72.3 monoclonal antibody labeled with 152 MBq of indium 111. Patients underwent scanning 2 to 3 days and 7 days after infusion by planar and emission computed tomography. Nineteen lesions were confirmed in 12 patients. Three patients with benign polyps had true-negative monoclonal antibody scans. Indium 111–labeled imaging of B72.3 detected nine of 19 lesions. Unsuspected tumor sites were identified by monoclonal antibody scan in three patients. By detection of additional abdominal disease and extra-abdominal spread, indium 111–labeled scanning of B72.3 directly affected treatment in 18% of patients.

(Arch Surg. 1990;125:1601-1605)